ZS Pharma, Inc. (ZSPH) [Rocket]

Overview

ZS Pharma, Inc. (ZSPH)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Price:	$89.98			Metrics
OS:	25.2	M		-55	% ROE
Market cap:	$2.26	B		-70	% ROIC
Net cash:	$197	M		$7.82	per share
EV:	$2.07	B

TTM Valuation
EBITDA	($104)	M
EBIT	($106)	M
EPS	($5.48)

Recent News + Filings (All items)

Date Filed	Type	Description
02/16/2016	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/29/2015	4/A	Form 4/A - Statement of changes in beneficial ownership of securities [Amend]
12/21/2015	4	DEVON PARK BIOVENTURES LP (10% Owner) has filed a Form 4 on ZS Pharma, Inc.
12/21/2015	4	RASMUSSEN HENRIK S MD (Chief Medical Officer) has filed a Form 4 on ZS Pharma, Inc.
12/21/2015	4	OSTRO MARC (Director) has filed a Form 4 on ZS Pharma, Inc.
12/21/2015	4	Babler Martin (Director) has filed a Form 4 on ZS Pharma, Inc.
12/21/2015	4	NOHRA GUY P (Director) has filed a Form 4 on ZS Pharma, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-14	Dec-31-13	Dec-31-12
Revenues	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0
Research and development	45.6	24.8	7.0
General and administrative	14.9	7.4	1.1
EBIT	-57.5	-30.8	-8.1
Pre-tax income	-64.0	-33.6	-10.3
Income taxes	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%
Net income	-64.0	-33.6	-10.3

Diluted EPS	($5.44)	($21.41)	($6.62)
Shares outstanding (diluted)	11.8	1.6	1.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy